Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167030 | 1.00 | SLC6A1 (0.65) | SLC6A1CYP2D6 | |
| SCHEMBL7167028 | 1.00 | SLC6A1 (0.65) | SLC6A1CYP2D6 | |
| SCHEMBL5501956 | 0.86 | MEN1 (0.50) | SLC6A1CYP2D6 | |
| SCHEMBL7166855 | 0.85 | MEN1 (0.58) | SLC6A1CYP2D6 | |
| SCHEMBL7166860 | 0.85 | MEN1 (0.58) | SLC6A1CYP2D6 | |
| SCHEMBL6693594 | 0.85 | SLC6A1 (0.60) | SLC6A1 | |
| SCHEMBL5500341 | 0.85 | SLC6A1 (0.60) | SLC6A1 | |
| Hydrochloric Acid SCHEMBL7164032 | 0.85 | MEN1 (0.49) | SLC6A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL7172024 | 0.84 | SLC6A1 (0.59) | SLC6A1 | |
| SCHEMBL7609408 | 0.83 | SLC6A1 (0.81) | SLC6A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | SLC6A1 3399/4885CYP2D6 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.